18 results about "Biodistribution" patented technology

There is disclosed a system for delivery of a drug in vivo. In the delivery system, the extent of the delivery of the drug is monitorable and / or controllable by using chemical exchange saturation transfer magnetic resonance imaging (CEST MRI). The delivery system has elements of a solvent system of dimethyl sulfoxide (DMSO) or its analogs for carrying the drug, detecting the delivery and / or biodistribution the drug, and / or interaction of the drug compartmentalized in vivo by way of directly imaging the solvent system by the CEST MRI due to the inherent contrast of the solvent system.

The near-infrared window of fluorescent heptamethine cyanine dyes greatly facilitates biological imaging because there is deep penetration of the light and negligible background fluorescence. But dye instability, aggregation, and poor pharmacokinetics are current drawbacks that limit performance and the scope of possible applications. All these limitations are simultaneously overcome with a new molecular design strategy that produces a charge balanced and sterically shielded fluorochrome. The key design feature is a meso-Aryl group that simultaneously projects two shielding arms directly over each face of a linear heptamethine polyene. Cell and mouse imaging experiments compared a shielded heptamethine cyanine dye (and several peptide and antibody bioconjugates) to benchmark heptamethine dyes and found that the shielded systems possess an unsurpassed combination of photophysical, physiochemical and biodistribution properties that greatly enhance bioimaging performance.

Aspects of the invention provide an AAV product that delivers an FXN gene supplementation or replacement strategy throughout the human CNS and heart at levels of DNA biodistribution, RNA expression, and FXN protein levels expected to restore function in Friedrich's ataxia patients.

Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and / or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

The present invention relates to near-infrared fluorescent heptamethine dyes and conjugates of heptamethine dyes with favourable biodistribution and bleaching properties.

Provided herein are engineered AAV capsids with improved biodistribution and transduction efficiency in microglia, e.g., in the brain, compositions comprising the capsids, and methods of using the same.

The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and / or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

The present disclosure provides a compound of formula (I) [Formula 1] TIFF2026500338000155.tif27165 or a pharmaceutically acceptable salt thereof, and uses thereof, for example, in assessing the biodistribution and / or concentration of a biomolecule in a subject.

The present invention relates to compounds comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib), each comprising an N-terminal modification group A comprising a biodistribution modulator, where the N-terminal modification group A is linked to Xaa1, and each comprising a C-terminal group C-terminal comprising a biodistribution modulator, where the C-terminal group C-terminal is linked to Xaa11. (Ia) and (Ib).

The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and / or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

Aspects of the invention provide an AAV product that delivers an GBA1 gene supplementation strategy throughout the human CNS at levels of DNA Biodistribution, RNA expression, and GBA1 protein levels expected to restore function in patients with Parkinson's disease.

The present invention discloses a nanoparticle with acid stability, pH responsiveness and targeting Helicobacter pylori, as well as a preparation method and use. The nanoparticle has a core-shell structure; wherein the core structure is an amino-modified mesoporous iron oxide nanoparticle loaded with manganese porphyrin; and the shell structure is a polymer coating targeting Helicobacter pylori. The pH-sensitive nanoparticles prepared by the present invention have acid stability and good mucus permeability. The pH-sensitive nanoparticles can accurately target Helicobacter pylori in the stomach. Magnetic resonance imaging (MRI) based on the particles can provide real-time information on the biodistribution of the drug in the body, guide ultrasonic irradiation when the drug release is maximum, and activate the drug to produce 1 O2 can eliminate Helicobacter pylori, and its inhibitory effect on Helicobacter pylori in vivo is comparable to that of antibiotic-based triple therapy, but it has no obvious mammalian cell toxicity and interference with normal intestinal flora, and has better biosafety.

Antibodies having enhanced biodistribution and / or pharmacokinetics obtained through conjugation of a negatively charged organic moiety are provided. Also provided are methods of enhancing the biodistribution and / or pharmacokinetics of an antibody. The enhanced antibodies find use in immunotherapy, radiotherapy, and in vivo imaging.

The present disclosure provides a modified AAV capsid protein containing a targeting peptide in variable region VIII (VR VIII). The modified AAV capsid protein can form a rAAV with preferred tropism, specificity, or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapy targeted to specific tissues. The targeting peptide has the sequence X1X2X3X4X5X6X7X8X9, where X1, X2, X3, X4, X5, X6, X7, X8, and X9 are each independently selected from any amino acid residue.

The present application relates to a method for improving the accuracy of in vivo cell tracking using iron chelators, comprising the following steps: S1, preparing drug materials; S2, preparing animals and cells: preparing bone marrow cells, S3, removing free iron chelators in vivo 89 Zr and 68 Ga, S4, radiolabeling mesenchymal stem cells and bone marrow cells; S5, performing Micro-PET imaging: S6, performing Micro-PET imaging data processing and analysis: S7, in vitro biodistribution; S8, performing pharmacokinetic studies; S9, extracting hAlu genomic DNA and performing qPCR detection; S10, establishing a standard curve of cell number and cycle threshold; S11, performing absorbed dose estimation; S12, performing in vitro cell experiments; S13, final statistical analysis. The present application provides a method for improving the accuracy of in vivo cell tracking using iron chelators, which realizes the effect of removing free radioactive metal ions in vivo using iron chelators, and ensures the accuracy of in vivo tracking labeled cells.

Methods are disclosed for electronically labeling and systemically administering radiotracers for targeted diagnostic and therapeutic applications, including immunomodulation. Radiotracers are electronically radiolabeled via direct application to a conductive conductor and delivered systemically through trans-vascular absorption, enabling controlled biodistribution confined to the conductor contact and minimizing off-target exposure. Real-time imaging permits monitoring of radiotracer distribution and activity during administration. Applications include immune modulation for suppression, ablation, or stimulation, as well as activation of non-radioactive precursors for diagnostic and therapeutic use. These methods are applicable to cancer, infectious disease, and autoimmune disorder treatment. Parameters such as radiotracer choice, radioactive activity, precursor formulation, dosing schedule, and administration duration may be adjusted individually or in combination to achieve the desired outcome. These techniques provide reproducible, controllable radiotracer delivery suitable for both imaging and therapy with integrated monitoring.

The present invention relates to fibronectin-binding peptides according to the sequenceFnI5BS-L1-FnI4BS-L2-FnI3BS-L3-FnI2BSwhich are useful in tumor or fibrosis diagnosis and therapy. Instant peptides show improved fibronectin-binding and biodistribution properties compared to the prior art. Furthermore, instant peptides may be conjugated to a payload and are useful in the treatment and / or prevention of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis. Instant peptides are also useful in diagnosis of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis.